Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2006

View Archived Issues

Alpha-defensin treatment for proliferative retinopathy that complicates diabetes and prematurity

QW-1624F2-2 active against human neuroblastoma in vivo

Enriched enteral formulation benefits children with lung injury, adults with sepsis

ImQuest and Samjin form drug development alliance

Analgesic effects of targeting iNOS in neuropathic and inflammatory pain

Fast track designation for Phenoptin in PKU

NicVAX completes phase II dose-ranging study, set for proof-of-concept trial

Toyama and Astellas sign letter of intent for oral T-3811 in Japan

Oral iclaprim shows good oral bioavailability

Rigel to receive milestone payment for R-763

AeroLEF studied in phase IIb trial for moderate to severe acute pain

Phase III trial for antidepressant vilazodone

Phase III pivotal trial protocol submitted for APF-530

Japanese approval for Abilify

Eculizumab arrests chronic intravascular hemolysis in PNH patients

SCH-336: CB2 agonist with potent antiinflammatory activity

Novel agents imparted for the treatment of arthritis and related disorders

New compounds for respiratory disorders prepared and tested

Recent Carlsson and Abbott patents describe new therapeutic agents for anxiety, depression, etc.

Sutent approved for advanced renal cell carcinoma and malignant GIST

Exubera approved in Europe and the U.S.

Positive opinion for Myozyme for Pompe disease in Europe

Ranexa approved for chronic angina

Quarterly i.v. Bonviva injection recommended for approval in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...